Charles River Laboratories (CRL) Tops Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2017 Results from Continuing Operations and Provides 2018 Guidance
February 13, 2018 7:01 AM ESTFourth-Quarter Revenue of $478.5 Million and Full-Year 2017 Revenue of $1.86 Billion
Fourth-Quarter GAAP Loss per Share of $0.63 and Non-GAAP Earnings per Share of $1.40
Full-Year GAAP Earnings per Share of $2.54 and Non-GAAP Earnings per Share of $5.27
Provides 2018 Guidance
ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE MPI RESEARCH
WILMINGTON, Mass--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2017 and provided guidance for 2018. For the quarter, revenue from continuing operations was $478.5 million, an increase of 2.5% from $466.8... More
